Design
THP-1 cells were differentiated into macrophages in 40 nM phorbol 12-myristate 13-acetate (PMA) for 30 h and treated with the following controls for 20 h in complete RPMI (cRPMI) supplemented with 0.5% (v/v) DMSO: 0.5% DMSO alone, Sendai virus (SeV) (100 HAU/mL) or interferon β (IFNβ; 100 IU/mL). Alternatively, cells were treated in the same manner with the compounds KIN1400, KIN1408, or KIN1409 at doses of 10 μM, 2.5 μM, and 0.625 μM. As an additional control, another set of cells were transfected with 2 μg/mL RIG-I agonist hepatitis C virus (HCV) polyU/UC RNA (pU/UC) or control HCV RNA XRNA in cRPMI without DMSO.
Compounds
Compounds were synthesized by Life Chemicals Inc. and KINETA, Inc. and were solubilized in 100% DMSO and kept frozen as 10 mM stocks. The compounds were stored in small aliquots to prevent multiple freeze-thaws and were step-wise diluted to reach the desired concentration in 0.5% DMSO for all treatments [2] . 
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Genomics Data j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / g d a t a were differentiated into macrophages in complete RPMI supplemented with 40 nM PMA for 24 h prior to their use in experiments.
Microarray analysis
Differentiated THP-1 cells treated with complete RPMI supplemented with 0.5% (v/v) DMSO with small molecule (KIN1400, KIN1408 and KIN1409 at 10, 2.5 or 0.625 μM), IFNβ 100 U/mL, SeV (Sendai virus) 100 HAU/mL or 0.5% DMSO alone. Additional cells were transfected with HCV polyU/UC RNA (2. μg/ml) or XRNA (2 μg/mL) using the TransIT®-mRNA Transfection reagent (Mirus Bio LLC). Cells were harvested 20 h later in RLT buffer. RNA was purified using Qiagen RNeasy kits and submitted to Labcorp, Seattle, WA for microarray analysis using Agilent SurePrint G3 Human Genome Microarrays (version 2).
Microarray data has been uploaded to Gene Expression Omnibus (GSE74047) [3] . All downstream analysis was performed by the Gale lab using R (version 3.2.1)/Bioconductor (version 3.1) and R studio (Version 0.99.486). The analysis was captured in a reproducible data report using RMarkdown [4] and can be found at http://ciiid.washington. edu/r_markdown/data_in_brief_012916/. Raw data was downloaded, background corrected and quantile normalized. Controls and low expressing probes were filtered and then applied to a linear model using the limma package (version 3.24.15) [5, 6] . Genes with significant expression changes following treatment were defined by those with a N 2-fold increase or decrease over DMSO (for small molecule compounds, IFNβ and SeV) or XRNA (for pU/UC PAMP RNA) controls with a Benjamini-Hochberg corrected (adjusted p-value) b 0.01. The gene expression heat map (Fig. 1) was clustered in R using Spearman correlation distances and Gene Ontology Biological Processes enriched in lists of genes mapping to clusters by DAVID 6.7 [7, 8] . Genes with Fig. 1 . Genomics analysis of KIN1400, KIN1408 and KIN1409 treatment. PMA differentiated THP-1 cells were treated with 10, 2.5 and 0.625 μM of compounds KIN1400, KIN1408 and KIN1409 for 20 h. (A) Heat map of the union of differentially expressed genes across treatments. Differential gene expression was defined as at least a 2-fold change in expression and a Benjamini-Hochberg corrected p-value b0.01 as compared to the appropriate negative control (XRNA for pU/UC RNA and DMSO for all other samples). Expression levels not meeting the cutoff thresholds were set to zero for visual identification of differential expression. Gene clusters identified by hierarchical clustering using spearman correlation as a distance measure and then classified by the most highly enriched gene ontology biological process meeting a Benjamini-Hochberg corrected p-value b0.05. predicted IRF7 binding sites according to the UCSC Genome Browser database were identified using Enrichr [9] . Finally, genes mapping to the Reactome Homo sapiens interferon alpha/beta signaling pathway (R-HAS-909,733) were identified using InnateDb [10] .
Conclusion
Transcriptional analysis of the parental small molecule KIN1400 compared to its medicinal chemistry-derived analogs showed that all three family members induced comparable gene expression profiles. The 1408 and 1409 analogs are, if anything, slightly more selective in their induction and repression of specific gene sets while retaining antiviral potency [1] , suggesting that medicinal chemical modifications may lead to the design of small molecules with fewer off-target effects. We also compared our IRF3 activating molecules to several control compounds. SeV infection is recognized by the cytoplasmic pathogen recognition receptor RIG-I, leading to activation of IRF-3 through MAVS. We included transcriptional analysis of THP-1 cells infected with SeV to identify the gene sets triggered during a natural infection. We also transfected the cells with the HCV polyU/UC RNA, which is known to directly engage RIG-I to signal to IRF-3 specifically through MAVS [11] , and compared the result to transfection with signalingdeficient HCV XRNA as a control. Finally, IFNβ was added to the cells to identify genes induced through JAK/STAT signaling by the type I interferon (IFN) receptor. We found that our small molecules were able to activate IRF7-dependent genes (whose binding site highly overlaps with that of IRF3) and type-I IFN signaling molecules in similar overall patterns to that of the controls. Additionally, our small molecules induced new modules of genes that are distinct from the traditional IRF3-activating controls, indicating that there may be additional factors involved. Further studies will be conducted to identify the mechanisms underlying these signatures.
The demand for broad-spectrum antivirals increases as new RNA viruses emerge or re-emerge to cause disease and impact public health. Our transcriptional analysis of the hydroxyquinoline family of compounds showed that it activates IRF signaling and promotes cellular antiviral responses. Additional analysis of these gene signatures could aid in the development of new antiviral therapies and further refine the mechanisms that enhance host-driven antiviral immune responses against a variety of RNA viruses.
